Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study

Movement Disorders

Volumn 31, Issue 12, 2016, Pages 1820-1828

  Vilas, Dolores ^a   Segura, Bàrbara ^b   Baggio, Hugo C ^b   Pont Sunyer, Claustre ^a   Compta, Yaroslau ^a,c,d   Valldeoriola, Francesc ^a,c,d   José Martí, María ^a,c,d   Quintana, María ^a   Bayés, Angels ^e   Hernández Vara, Jorge ^f   Calopa, Matilde ^g   Aguilar, Miquel ^g   Junqué, Carme ^b,c,d   Tolosa, Eduardo ^a,c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e CENTRO MÉDICO TEKNON   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

connectivity; functional MRI; LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN; BRAIN SIZE; CLINICAL ARTICLE; CORPUS STRIATUM; CORTICAL THICKNESS (BRAIN); FEMALE; FUNCTIONAL CONNECTIVITY; FUNCTIONAL NEUROIMAGING; GENE MUTATION; GRAY MATTER; HETEROZYGOTE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; PRECUNEUS; PRIORITY JOURNAL; REST; VOXEL BASED MORPHOMETRY; BRAIN CORTEX; CONNECTOME; DIAGNOSTIC IMAGING; GENETICS; MIDDLE AGED; MUTATION; NEOSTRIATUM; NUCLEAR FAMILY; PATHOPHYSIOLOGY; PROCEDURES; PRODROMAL SYMPTOM; SUBSTANTIA NIGRA;

ADULT; CEREBRAL CORTEX; CONNECTOME; FEMALE; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOSTRIATUM; NUCLEAR FAMILY; PARKINSON DISEASE; PRODROMAL SYMPTOMS; SUBSTANTIA NIGRA;

EID: 84992512762     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26799     Document Type: Article

References (40)

1. West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord 2015;30(2):180–189.
2. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009;72(7Suppl):S12–S20.
3. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7):583–590.
4. Gaig C, Vilas D, Infante J, et al. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease. PLoS One 2014;9(10):e108982.
5. Marras C, Schule B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77(4):325–333.
6. van der Vegt JP, van Nuenen BF, Bloem BR, Klein C, Siebner HR. Imaging the impact of genes on Parkinson's disease. Neuroscience 2009;164(1):191–204.
7. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128(Pt12):2777–2785.
8. Sierra M, Sanchez-Juan P, Martinez-Rodriguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013;80(7):621–626.
9. Reetz K, Tadic V, Kasten M, et al. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 2010;39(3):402–408.
10. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26(13):2335–2342.
11. Thaler A, Mirelman A, Helmich RC, et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 2013;49(9):2501–2511.
12. van Nuenen BF, Helmich RC, Ferraye M, et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012;135(Pt12):3687–3698.
13. Helmich RC, Thaler A, van Nuenen BF, et al. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology 2015;84(4):399–406.
14. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006;63(3):377–382.
15. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129–170.
16. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995;4(1):93–97.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361–370.
18. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory. San Antonio, TX: Psychological Corporation; 1996.
19. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19(11):1306–1312.
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–198.
21. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33(3):341–355.
22. Douaud G, Smith S, Jenkinson M, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007;130(Pt9):2375–2386.
23. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012;59(3):2142–154.
24. Liu Y, Liang M, Zhou Y, et al. Disrupted small-world networks in schizophrenia. Brain 2008;131(Pt4):945–961.
25. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage 2014;92:381–397.
26. Abdi H. Bonferroni and sidak corrections for multiple comparisons. In: Salkind NJ, ed. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: Sage; 2007:103–107.
27. Sharman M, Valabregue R, Perlbarg V, et al. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord 2013;28(4):447–454.
28. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012;135(Pt12):3699–3711.
29. Agosta F, Caso F, Stankovic I, et al. Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism. Neurobiol Aging 2014;35(11):2592–2602.
30. Luo C, Song W, Chen Q, et al. Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study. Neurobiol Aging 2014;35(2):431–441.
31. Ellmore TM, Castriotta RJ, Hendley KL, et al. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep 2013;36(12):1885–1892.
32. Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.
33. Chai XJ, Castañón AN, Ongür D, Whitfield-Gabrieli S. Anticorrelations in resting state networks without global signal regression. Neuroimage 2012;59(2):1420–1428.
34. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A 2005;102(27):9673–9678.
35. Baggio HC, Segura B, Sala-Llonch R, et al. Cognitive impairment and resting-state network connectivity in Parkinson's disease. Hum Brain Mapp 2015;36(1):199–212.
36. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010;67(6):584–587.
37. Harrington DL, Rubinov M, Durgerian S, et al. PREDICT-HD investigators of the Huntington Study Group, Rao SM. Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain 2015;138(Pt8):2332–2346.
38. Pereira JB, Ibarretxe-Bilbao N, Marti MJ, Compta Y, Junqué C, Bargallo N, Tolosa E. Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012;33(11):2521–2534.
39. Thaler A, Artzi M, Mirelman A, et al. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. Mov Disord 2014;29(6):823–8277.
40. Parisiadou L, Yu J, Sgobio C, et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci 2014;17(3):367–376.